Cholinesterase Inhibitors in the Management of Canine Cognitive Dysfunction: A Review on the Mechanisms of Action, Current Evidence from Experimental and Clinical Studies, and Future Directions
Year: 2026
Type: article
Abstract: Canine cognitive dysfunction is a progressive, age-related neurodegenerative disorder that shares several clinical and neuropathological features with human Alzheimer’s disease, although important differences exist between the two conditions. The central mechanisms underlying the pathophysiology of canine cognitive dysfunction include the accumulation of amyloid-β plaques, cytoplasmic deposits of phosphorylated tau protein with rarely observed neurofibrillary tangles, cortical brain atrophy, and disturbances in neurotransmitters, particularly within cholinergic pathways. Compared with those in age-matched, cognitively unimpaired and young cohorts, the number of cholinergic neurons in the basal forebrain in old, cognitively impaired dogs is significantly lower. However, cholinergic deficit does not correlate directly with cortical amyloid-β load. These neurochemical and structural changes contribute to the characteristic cognitive and behavioral deficits of canine cognitive dysfunction. Cholinesterase inhibitors, which increase synaptic acetylcholine levels by inhibiting acetylcholinesterase and/or butyrylcholinesterase, have emerged as a promising pharmacological strategy. This review critically evaluates current evidence from experimental studies investigating the effects of cholinesterase inhibitors on age-associated cognitive performance in laboratory beagle dogs, as well as clinical studies involving client-owned dogs diagnosed with canine cognitive dysfunction; describes their mechanistic basis; and outlines currently available symptomatic pharmacological interventions, such as the monoamine oxidase B inhibitor selegiline (L-deprenyl), and non-pharmacological interventions, including environmental enrichment, regular exercise, diet, and nutritional supplements. Furthermore, it identifies knowledge gaps and proposes future research directions that could support the translation of cholinesterase inhibitors into effective therapeutic interventions for improving cognitive function and quality of life in aging dog populations.
Source: Animals
DOI: 10.3390/ani16223692
Author: Tomaž Trobec
Institution: University of Ljubljana
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: canine cognitive dysfunction, cholinesterase inhibitors, acetylcholinesterase, butyrylcholinesterase, cholinergic deficit, amyloid plaques, tau phosphorylation, neurofibrillary tangles, cortical atrophy, selegiline, monoamine oxidase B inhibitors, environmental enrichment, physical activity, dietary supplements, canine aging, Alzheimer's disease comparison, beagle dogs
Open Access status: gold
Estimated APC paid: $2,896
OpenAlex ID: W7237230288
